Esperion Therapeutics (ESPR) Tops Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.77), $0.05 better than the analyst estimate of ($0.82).
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- UBS Reiterates Buy Rating on Smurfit Westrock (SW)
- TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
